ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1069

ATG7 Drives Metabolic Cell-Fate Decisions in Kidney Tubule Homeostasis and Disease

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1500 Health Maintenance, Nutrition, and Metabolism

Authors

  • Luciani, Alessandro, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
  • Nieri, Daniela, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
  • Keller, Svenja Aline, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
  • Pierre, Louise, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
  • Chen, Zhiyong, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
  • Devuyst, Olivier, Universitat Zurich Physiologisches Institut, Zürich, ZH, Switzerland
Background

Specialized epithelial cells must coordinate metabolic pathways with differentiation cues to fulfil their functions and maintain homeostasis. A paradigm for this concept is provided by proximal tubule (PT) cells in the kidney, which require high energy to recover ultrafiltered proteins and solutes via endocytosis and lysosomal degradation. Simultaneously, autophagy recycles intracellular components to support energy metabolism and homeostasis. Central to autophagy biogenesis is ATG7 — a conserved E1-like enzyme that conjugates ATG12 to ATG5 and lipidates MAP1LC3-I into MAP1LC3-II, a bona fide biosensor of autophagy levels in cells and tissues. While ATG7-dependent autophagy is recognized for its role in resilience in response to cellular stressors, its basal function in shaping the metabolic PT cell-fate specialization remains poorly understood.

Methods

We integrated genetically engineered models (mouse, C. elegans, and zebrafish) with physiologically relevant PT cell cultures, functional lipid metabolism assays (e.g., pulse-chase using fluorescent lipid droplet and fatty acid probes), multi-omics analyses, and human genetics to investigate the role of ATG7 in PT cell-fate decisions and determination.

Results

In mice, PT-specific deletion of ATG7 forces differentiated cells into anabolic, proliferative states, leading to the appearance in the urine of essential nutrients and causing proximal tubulopathy. Mechanistically, loss of ATG7 impairs the clearance of lipid droplets, restricts fatty-acid (FA) metabolism, and depletes cellular energy required for transport and reabsorptive functions. In zebrafish pronephros, re-expression of wild-type ATG7 rescues reabsorption in atg7 mutants, whereas inhibiting FA oxidation triggers dysfunction. In humans, ATG7 variants associate with cardio-renal-metabolic health and increased kidney disease risk, whereas low ATG7 levels predict poor survival in clear cell renal carcinoma.

Conclusion

Taken together, these findings establish a conserved paradigm coupling ATG7/autophagy and lipid energy metabolism to epithelial cell-fate specialization in the kidney tubule, thus carrying implications for health, disease, and therapeutic discovery.

Digital Object Identifier (DOI)